Rexulti Tablet
Product Images NDC 70518-3548

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Rexulti (NDC 70518-3548). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Rexulti is a medication sold in a pack of 30 tablets. Each tablet contains 2 mg of Brexpiprazole. This medication is manufactured in Tokyo, Japan by Otsuka Pharma Co. Ltd. The medication is RX ONLY and the NDC number for the same is 70518-3548-00. The lot number and expiry date are missing from the available text. The medication should be stored at room temperature between 20-25°C (88-77°F) with excursions allowed from 15-30°C (59-86°F) according to USP. For usage directions, refer to the package insert. The medication has been repackaged by RemedyRepack Inc. located in Indiana, PA 15701. Keep the medication out of reach of children.*

FDA Label Image

Chemical Structure (Rexulti Chem Structure)

FDA Label Image

Figure 1 (Rexulti Figure 01)

FDA Label Image

Figure 2 (Rexulti Figure 02)

This appears to be a table showing changes in Brexpiprazole PK (pharmacokinetics) due to certain measures such as CYP3A4 inhibitors and inducers, CYP2D6 inhibitors, gastric PH increase, etc. The table shows the changes as fold change and 90% confidence intervals. The interacting drugs mentioned are Crmex, Ketoconazole, Cmex, Quinidine, Rifampin, Cmax, Ticlopidine, and Omeprazole. However, without more context it is difficult to provide a specific and practical application of this information.*

FDA Label Image

Figure 3 (Rexulti Figure 03)

This appears to be a table displaying the effect of various drugs on certain substrates. The substrates listed are CYP2D6, PgP, CYP286, CYP3A4, and BCRP. The table lists the PK fold change and 90% confidence intervals for various analytes measures on urine, including Dextromethorphan, Fexofenadine, Bupropion, Lovastatin, and Roswastatin. There is also a column displaying the change relative to a reference without the interacting drug.*

FDA Label Image

Figure 4 (Rexulti Figure 04)

This text seems to describe a comparison in the efficacy of two treatments for a medical condition. One treatment is ADT with placebo, and the other is ADT with Brexpiprazole 2 mg. However, the text is incomplete and lacks context, so it is hard to provide further details.*

FDA Label Image

Figure 5 (Rexulti Figure 05)

FDA Label Image

Figure 6 (Rexulti Figure 06)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.